期刊
CURRENT OPINION IN PSYCHIATRY
卷 24, 期 1, 页码 49-54出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/YCO.0b013e32833f5585
关键词
anxiety; attention; cognition; memory; metacognition
类别
资金
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Janssen-Cilag
- Otsuka Pharmaceutical
- Pfizer
- Schering-Plough
- Wyeth
Purpose of review Cognitive dysfunction is frequently reported in anxiety disorders. Our aim is to describe recent advances concerning these cognitive aspects. Recent findings Cognitive dysfunction in anxiety disorders can be classified into four domains. The first concerns executive functions, mainly attentional processes. The second concerns memory, including deficits in working, episodic, and autobiographical memory. The third encompasses maladaptive cognitions, or thoughts and beliefs. Finally, a burgeoning area of research (mainly in obsessive - compulsive disorder and posttraumatic stress disorder) concerns metacognitions, or thoughts and beliefs about one's own thoughts and beliefs. All of these dysfunctions may contribute to maintain or aggravate anxiety disorders. When developing and implementing interventions, researchers and clinicians alike must consider these cognitive aspects, and may need to tailor their approaches accordingly. Summary Advances have clearly been made in the elucidation of the cognitive functioning associated with anxiety disorders. It remains unclear if particular cognitive profiles can help to distinguish anxiety disorders from one another, although emerging evidence suggests this may be the case. Further clarification will add to our understanding of the development and maintenance of these disorders, and may provide targets for future therapy and endophenotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据